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Background: Human angiosarcoma and canine hemangiosarcoma are thought to arise from vascular tissue or
vascular forming cells based upon their histological appearance. However, recent evidence indicates a hematopoietic
or angioblastic cell of origin for these tumors. In support of this idea, we previously identified an endothelial-myeloid
progenitor cell population with high expression of endothelial cell markers and the myeloid cell marker, colony
stimulating factor 1 receptor (CSF-1R). Here, we further characterized these cells to better understand how their
cellular characteristics may impact current therapeutic applications.
Methods: We performed cell enrichment studies from canine hemangiosarcoma and human angiosarcoma cell
lines to generate cell populations with high or low CSF-1R expression. We then utilized flow cytometry, side
population and cell viability assays, and fluorescence based approaches to elucidate drug resistance mechanisms
and to determine the expression of hematopoietic and endothelial progenitor cell markers.
Results: We demonstrated that cells with high CSF-1R expression enriched from hemangiosarcoma and angiosarcoma
cell lines are more drug resistant than cells with little or no CSF-1R expression. We determined that the increased drug
resistance may be due to increased ABC transporter expression in hemangiosarcoma and increased drug sequestration
within cellular lysosomes in both hemangiosarcoma and angiosarcoma.
Conclusions: We identified drug sequestration within cellular lysosomes as a shared drug resistance mechanism in
human and canine vascular sarcomas marked by high CSF-1R expression. Taken together, our results demonstrate that
studies in highly prevalent canine hemangiosarcoma may be especially relevant to understanding and addressing drug
resistance mechanisms in both the canine and human forms of this disease.
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Human angiosarcoma and canine hemangiosarcoma are
aggressive malignancies of vascular tissue or vascular
forming cells [1,2], and their morphology and pathological
progression are virtually indistinct. Although doxorubicin
remains the foundation of chemotherapy for humans and
dogs, it provides minimal tumor control or survival bene-
fit for angiosarcoma patients as only 16-36% of patients
respond to treatment and over 50% of affected dogs still
die within four to six months of their diagnosis [1,2]. In* Correspondence: edickers@umn.edu
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unless otherwise stated.addition to their poor response rates, tumors in both spe-
cies can be highly drug resistant. Thus, the outcomes of
people and dogs are not likely to improve without an in-
creased understanding of the biology and pathogenesis of
these tumors. To complicate matters further, angiosarco-
mas occur infrequently restricting the study of their basic
biology and clinical treatment [3]. However, the frequent
occurrence of hemangiosarcomas in dogs (up to 7% of all
canine malignancies) [4] provides a readily available re-
source to investigate tumor biology and explore related
treatment options.
Identifying more successful treatment approaches may
lie in addressing the cellular origin of these tumors rather
than their histological appearance. Canine hemangiosarcomal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tumors of malignant endothelium due to their histology
and the expression of endothelial cell surface markers
[2,5]. Based on the expression of early hematopoietic and
endothelial progenitor markers, other studies have chal-
lenged this idea, suggesting instead that hemangiosarco-
mas might arise from bone marrow-derived angioblastic
progenitors [6-8]. A similar analogy of progenitor cell ori-
gin has been drawn for human angiosarcoma [9].
In a more recent analysis, we identified and character-
ized a myeloid subpopulation from hemangiosarcoma
cell lines that showed the expression of markers associ-
ated with bone marrow-derived myeloid progenitors
(CD14 and CD115 or the colony stimulating factor 1 re-
ceptor, CSF-1R) co-expressed with surface markers asso-
ciated with endothelial progenitor (CD34 and CD133)
and endothelial cell differentiation (CD105, CD146, and
αvβ3) [8]. These cells also possessed phagocytic activity,
and the co-expression of endothelial markers suggests a
role in angiogenesis. Yoder et al. described a similar
population of human myeloid cells that express a variety
of hematopoietic (CD14, CSF-1R, and CD45) and endo-
thelial markers (CD133, CD34, VEGFR2) and participate
in blood vessel formation [10]. These cells possessed a
myeloid progenitor cell activity and differentiated into
phagocytic macrophages, but failed to contribute to the
capillary endothelial layer in vivo. These similarities suggest
that the myeloid-endothelial cell phenotype in hemangio-
sarcoma may represent a viable target for therapeutic inter-
vention, and more specifically, targeting of CSF-1R.
CSF-1R and its ligands, CSF-1 and IL-34, are com-
monly associated with the survival, proliferation, differ-
entiation, and activation of mononuclear phagocytes
[11-15]. CSF-1R expressed by tumor associated macro-
phages (TAMs) can have therapeutic implications since
TAMs impact tumor growth by promoting myeloid cell-
mediated angiogenesis, chemoresistance, and metastatic
spread [16-20]. However, expression of CSF-1R by tumor
cells also indicates a non-macrophage functional role for
the receptor. In this regard, Cioce et al. reported increased
expression of CSF-1R mRNA in mesothelioma versus nor-
mal tissue specimens and demonstrated that CSF-1R ex-
pression identified chemoresistant cells in both primary
cultures and mesothelioma cell lines [21]. Thus, CSF-1R
expression may serve as a marker to identify drug resistant
populations in some cancers.
For this study, we demonstrate that both hemangiosar-
coma and angiosarcoma cells with high expression of
CSF-1R are more drug resistant than their CSF-1R low-
expressing counterparts, indicating a shared mechanism
for the observed treatment failures and subsequent drug
resistance. Our data also suggest that part of this resist-
ance may be achieved through drug sequestration within
cellular lysosomes. Intriguingly, drug resistance in caninehemangiosarcoma is associated with CD133 expression,
suggesting that resistance may be associated with a stem
or progenitor cell phenotype and may be related to the de-
gree of cellular differentiation. Further characterization of
these cells and utilization of approaches to disrupt lyso-




The DD-1 cell line was derived from a splenic heman-
giosarcoma [22], and the COSB line was derived from a
xenograft of the original cell line, SB-HSA [23]. The AS5
human angiosarcoma cell line was derived from a pri-
mary angiosarcoma of the thigh [24]. All cell lines were
cultured as described previously [6,22,25]. Cells were
maintained in culture for up to 8 weeks before new vials
were thawed to ensure similar passage numbers were
used for all experiments.
Flow cytometry and magnetic enrichment
The primary antibodies used were: anti-CSF-1R (CD115)-
Cy5.5 (Bioss Inc., Woburn, MA), anti-CD34-Alexa Fluor
647, anti-CSF-1R-RPE (AbD Serotec, Raleigh, NC); anti-
CD117(c-kit)-PE and APC, anti-CD34-PE, anti-CD243
(ABCB1)-PE and APC, anti-CD338 (ABCG2)-PE and APC
(eBioscience, San Diego, CA), anti-CD34-APC (human)
(eBioscience), anti-CD34-PE and APC (canine) (eBioscience),
and anti-CD133/AC133-PE and APC (Miltenyi Biotech,
Auburn, CA). The detection of cell surface markers was
carried out as described, previously [8]. Data were col-
lected on a BD FACS Calibur or a BD Accuri C6 flow
cytometer (BD Biosciences, San Jose, CA) and then an-
alyzed using FlowJo software. To exclude dead cells
from analysis, 7-AAD was added to cells 10 minutes
before acquisition, and compensation was performed to
account for 7-AAD fluorescence in FL2. CSF-1Rlow and
CSF-1Rhigh populations were enriched from hemangio-
sarcoma and angiosarcoma cells by staining 2 × 107 to
4 × 107 cells with anti-CD115-RPE antibody followed
by magnetic separation using the EasySep PE-Selection
Kit (Stemcell Technologies, British Columbia, Canada)
according to the manufacturer’s instructions. Cells were
analyzed immediately after enrichment by flow cytome-
try to determine the percent enrichment from the ori-
ginal cell line culture.
Phagocytosis assay
Cells were plated in triplicate using 10,000 cells per well
in 100 μL of culture medium. FITC-conjugated, rabbit-
IgG-coated latex beads (Cayman Chemical Company,
Ann Arbor, MI) were added to the cells. No beads were
added to negative control wells. The emission at 535 nm
was measured for each well after 24 hours using a
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cytosis for each cell line was determined by dividing the
fluorescence of the wells with beads by the fluorescence
of the respective negative controls.
Cytotoxicity assays
Cells were plated in triplicate at 2,500 (DD-1), 5,000
(COSB) or 10,000 (AS5) cells per well in 100 μL of cul-
ture medium and exposed to increasing concentrations
of doxorubicin (Bedford Laboratories, Bedford, OH).
Cell viability was determined 72 hours later using the
colorimetric Cell Titer 96® Aqueous Non-Radioactive
Cell Proliferation Assay (MTS Assay; Promega, Madison,
WI) according to the manufacturer’s instructions. In
order to compare the percent viability between the CSF-
1Rlow and the CSF-1Rhigh populations and reduce arti-
facts due to potential differences in metabolic properties
between cell populations, standard curves were gener-
ated for each CSF-1R population in each cell line, and
the cell viability was determined based upon the total
cell number from the standard curve. A separate stand-
ard curve for the CSF-1Rlow and the CSF-1Rhigh popula-
tions was generated for each experiment.
Side population analysis
Filtered DD-1 or COSB cells were incubated in the presence
or absence of 10 μM verapamil for 15 minutes at 37°C. Dye-
Cycle Violet (DCV) (Life Technologies, Eugene, OR) was
added to a final concentration of 10 μM, and the cells were
incubated for an additional 60 minutes at 37°C with inter-
mittent mixing. Cells were washed, filtered, and maintained
on ice until analysis. Propidium iodide was added to each
sample immediately before collection to exclude dead cells
from analysis. DCV emission was detected using a BD LSRII
flow cytometer (BD Biosciences). Verapamil was used
to determine the SP gates, and data were analyzed
using FlowJo software (Tree Star Inc.).
Doxorubicin assays and detection
Cells were plated at 100,000 cells per well in 3 mL of
culture medium in a 6-well plate. After 2 hours, cells
were treated with 1 μM doxorubicin for 1 hour, washed
with PBS, and stained for CSF-1R expression using a
Cy5.5 labeled CSF-1R antibody at t = 0 and 24 hours.
Intracellular doxorubicin was measured according to
established methods [26,27]. To exclude dead cells from
analysis, 7-AAD was added to filtered cells 10 minutes
before data acquisition and compensation was used to
account for the fluorescence of 7-AAD in FL2.
To determine the percent viable cells positive for CSF-
1R expression after doxorubicin exposure, COSB cells
were plated in triplicate as described for the cytotoxicity
assays. Cells were exposed to increasing concentrations
of doxorubicin (Bedford Laboratories) for 72 hours andthen harvested. Cells were stained for CSF-1R expression
using a Cy5.5 labeled CSF-1R antibody and 7-AAD was
added to the cells before analysis.
LysoTracker detection
Cell lines were grown until they were approximately
80% confluent and then harvested for analysis. The cells
were blocked with normal rat serum in cold PBS con-
taining 2% fetal bovine serum (Atlanta Biologicals, At-
lanta, GA) and 2 mmol/L EDTA (Sigma, St. Louis, MO)
for 2 minutes, and then incubated with an anti-CSF-1R-
RPE antibody (AbD Serotec) for 30 minutes on ice. After
incubation, the cells were washed with cold PBS to re-
move serum and incubated with increasing concentra-
tions of LysoTracker® Deep Red (Life Technologies) in
serum free medium on ice for 10 minutes. The cells
were centrifuged and washed with cold PBS. To exclude
dead cells from analysis, 7-AAD or LIVE/DEAD® Cell
Stain (Life Technologies) was added to the cells before
acquisition on an Accuri or BD LSRII flow cytometer
(BD Biosciences). The CSF-1Rhigh population (~1-2% of
the total cell population) was identified using anti-CSF-
1R RPE labeling. Approximately 3-5% of the dimmest
cell population was used to represent the CSF-1Rlow
population. The CSF-1R populations were normalized
for comparison by subtracting the background (cells
without LysoTracker, negative control) and then dividing
the median fluorescence intensity of each concentration
of LysoTracker by the median fluorescence intensity of
the each cell population without LysoTracker (negative
control). Values are presented as relative fluorescence
levels for comparison.
Statistical analysis and data presentation
All EC50 calculations were made using Prism 5 Software
(GraphPad Inc. San Diego, CA) using a 4-parameter
curve fit. Bar graphs are presented as blank-subtracted
(adjusted) means ± SD. Comparisons between groups
were made using a two-sided Student’s t-test to evaluate
statistical significance, and a p-value ≤ 0.05 was consid-
ered significant.
Results
CSF-1Rhigh populations can be enriched from
hemangiosarcoma and angiosarcoma cell lines and
hemangiosarcoma CSF-1Rhigh cells display increased
phagocytosis
Cell surface expression levels of CSF-1R were deter-
mined for the canine hemangiosarcoma cell lines COSB
and DD-1 and the human angiosarcoma cell line AS5 by
flow cytometry. Flow cytometry analysis showed that a
small percentage of cells (typically 1-2% of the cell
monolayer) expressed high levels of CSF-1R in each cell
line whereas the majority of the cells showed little to no
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cells expressing high levels of CSF-1R (CSF-1Rhigh) for
phenotypic and functional assays, we used CSF-1R anti-
body staining and enrichment with magnetic beads to
select for cells with high CSF-1R expression as well as to
obtain a subset of cells with low expression (CSF-1Rlow)
(Figure 1). The percentage of CSF-1Rhigh cells in the
enriched populations ranged from ~20-40% depending
on the cell line. As an example, a summary of the
enriched populations presented in Figure 1 is presented
in Additional file 1: Table S1.
To determine if the CSF-1Rhigh cells had retained or
acquired myeloid cell properties, we determined the cap-
acity of CSF-1Rlow and CSF-1Rhigh cells for phagocytosis.
Significant increases in phagocytic activity in the CSF-
1Rhigh cells enriched from the COSB (p = 0.003) and the
DD-1 (p = 0.034) cell lines were observed when com-
pared to their CSF-1Rlow counterparts, reaching a level
comparable to that observed in the mouse macrophage
cell line RAW 264.7 (Figure 2A). Phagocytosis also was










Figure 1 Enrichment of cells expressing CSF-1R (CSF-1Rhigh) from can
Monolayer cells were labeled with an RPE-CSF-1R antibody and enriched fo
were assessed by flow cytometry to determine the percentages of cells in eac
the receptor.from the AS5 cell line. Although the levels of phago-
cytosis were similar to those observed for the DD-1
CSF-1Rlow cell population, the difference between the
CSF-1Rhigh and the CSF-1Rlow cell populations was not
significant (p = 0.08) (Figure 2B). These results demonstrate
that enriched CSF-1Rhigh populations from hemangiosar-
coma and angiosarcoma cell lines can be obtained, and that
CSF-1Rhigh cell populations from the hemangiosarcoma cell
lines retain a myeloid-like character. Phagocytosis by endo-
thelial cells also has been described [28], and this is in keep-
ing with the myeloid-endothelial phenotype previously
identified for hemangiosarcoma cell lines [6,8].
High CSF-1R expression correlates with increased
resistance to doxorubicin
To determine if CSF-1Rhigh cells display differential drug
sensitivities versus the monolayer cell and CSF-1Rlow cell
populations, we conducted comparative assays using
doxorubicin, which is used commonly to treat both ca-
nine hemangiosarcoma and human angiosarcoma [1,2].
The relative viabilities of the monolayer, CSF-1Rlow, andCSF-1Rlow CSF-1Rhigh 
escence Intensity 
ine hemangiosarcoma and human angiosarcoma cell lines.
r CSF-1R expression using magnetic bead separation. Cell populations
h population showing low (CSF-1Rlow) or high (CSF-1Rhigh) expression of
AB
Figure 2 CSF-1Rhigh cells exhibit increased phagocytosis.
Phagocytosis of FITC-conjugated, IgG-coated latex beads was
assessed in (A) CSF-1Rlow and CSF-1Rhigh cells in hemangiosarcoma
cell lines and (B) in the angiosarcoma cell line, AS5. Phagocytosis is
represented as relative fluorescence intensity by each cell line. The
macrophage cell line, RAW264.7, was used a positive control for the
assay. The increased phagocytic activity in the CSF-1Rhigh populations
from the hemangiosarcoma cell lines was significant (COSB, p* = 0.003
DD-1, p* = 0.034) compared to the activity detected in CSF-1Rlow
populations. Statistical significance was not detected (p = 0.08)
between the CSF-1Rlow and the CSF-1Rhigh cell populations
enriched form the AS5 cell line.
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doxorubicin concentrations are shown in Figure 3. In
each case, the CSF-1Rhigh cell populations were more re-
sistant to doxorubicin when compared to both the
monolayer and CSF-1Rlow cell populations. The approxi-
mate EC50 values for each population are shown in par-
entheses. The EC50 values for the monolayer cell
populations were similar to, yet always slightly higher
than, those determined for the CSF-1Rlow cells. This re-
sult is consistent with the idea that the CSF-1Rlow cells
make up the bulk of the monolayer cell culture, but that
the contribution of the CSF-1Rhigh cells to drug resist-
ance can be observed. Non-overlapping 95% confidence
interval values for the CSF-1Rlow and CSF-1Rhigh cell
populations enriched from the COSB and DD-1 cell
lines (Additional file 1: Table S2) provide support for the
observed drug sensitivities. While overlap of the 95%
confidence intervals for the CSF-1Rlow and CSF-1Rhigh
cell populations from the AS5 cell line was noted, thedifferences in drug sensitivities were consistently repro-
ducible in our assays.
To further verify that the CSF-1Rhigh cells are respon-
sible for the observed increase in drug resistance, we
treated the COSB cell line with the increasing concen-
trations of doxorubicin for 72 hours and determined the
CSF-1R-expression by the cells remaining after treat-
ment (Additional file 2: Figure S1A and B). At the lowest
concentrations of doxorubicin, CSF-1Rlow cells com-
prised the majority of the cell population, but the num-
ber of CSF-1Rlow cells diminished as the concentration
of doxorubicin increased. At the highest concentrations,
the cell populations were comprised predominately of
cells expressing CSF-1R, indicating that CSF-1R expres-
sion can be utilized as a marker for drug resistant cell
populations.
CSF-1Rhigh cells from hemangiosarcomas express high
levels of ABCB1 and ABCG2 but show limited dye efflux
from their side populations
ABC transporters can efflux chemotherapy agents from
cancer cells to reduce intracellular drug accumulation
and prevent high level of drugs from reaching their
intended intracellular targets. Because doxorubicin can
be effluxed by the transporters ABCB1 (P-glycoprotein
or P-gp) or ABCG2 (breast cancer resistance protein or
BCRP) [29,30], we chose to examine the expression of
ABCB1 and ABCG2 in our cell lines and determine if
drug efflux might contribute to the observed resistance
in the CSF-1Rhigh populations.
We first examined ABC transporter expression in the
canine hemangiosarcoma cell lines (Figure 4A and 4B).
The expression levels of ABCB1 and ABCG2 in the
monolayer and the CSF-1Rlow cell populations from the
COSB cell line were relatively low (Figure 4A). However,
high expression of ABCB1 was displayed by a small per-
centage of the cells (approximately 5-8% of the total cell
population), and these cells were designated as “bright” on
the histograms to distinguish highly positive cells from
those with low (“dim”) transporter expression. ABCB1
and ABCG2 expression was detected in the monolayer
and the CSF-1Rlow cell populations from the DD-1 cell
line, and the expression patterns between the monolayer
and CSF-1Rlow cells were similar (Figure 4B). The COSB
and DD-1 CSF-1Rhigh cell populations showed increased
expression of ABCB1 and ABCG2 overall, and both popu-
lations displayed a bimodal expression pattern with sub-
stantial increases in the percentage of “bright” cells. In
contrast, ABCB1 and ABCG2 expression was low or not
detected in the populations from the AS5 cell line, and
the expression was restricted to the monolayer and CSF-
1Rlow cell populations (Additional file 2: Figure S2). Our
results suggest that ABCB1 and ABCG2 expression might



































Figure 3 CSF-1Rhigh cells show increased resistance to standard chemotherapy agents. Unenriched monolayer cells, CSF-1Rlow, or CSF-1Rhigh
cells enriched from hemangiosarcoma or angiosarcoma cell lines were treated with increasing concentrations of doxorubicin for 72 hours. The relative
viability was assessed using an MTS assay. The approximate EC50 values for each subpopulation are shown in parenthesis from representative
experiments. All conditions were performed in triplicate and error bars represent standard deviation.
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however, other transporters or mechanisms appear to be
involved in drug resistance in the AS5 cell line.
To further clarify the potential roles of ABCB1 and
ABCG2 in the CSF-1Rhigh cell-associated drug resist-
ance, we performed side population analysis using Dye-
Cycle Violet (DCV). DCV is a viable dye known to be
effluxed from cells by ABCB1 and ABCG2 [31,32]. We
did not perform this assay using the AS5 cells due to the
low cell surface expression of the ABC transporters.
Both the monolayer and CSF-1Rlow cell populations from
the COSB and DD-1 cell lines contained dye effluxing
populations ranging from approximately 2.2% (DD-1,
monolayer cells) up to about 4.7% (COSB CSF-1Rlow) of
the total cells (Figure 5A and B). These side populations
were highly sensitive to verapamil, which is a broad inhibi-
tor of ABC transporter activity that primarily affects
ABCB1 activity but affects ABCG2 activity at high con-
centrations [30,32].Although the side populations were almost completely
eliminated by verapamil in all cases, the dye excluding
populations identified in the CSF-1Rhigh cells (~1%) were
smaller than those observed in the monolayer and the
CSF-1Rlow cells (~2-5%). This was unexpected given the
more abundant expression of ABCB1 and ABCG2 by
the CSF-1Rhigh populations. This result prompted us to
look for other mechanisms of drug resistance since the
level of dye efflux (and potentially the level of ABC
transporter expression) by these cells may not corres-
pond to drug sensitivity.
CSF-1Rhigh cells show higher levels of intracellular
doxorubicin and LysoTracker suggesting increased
lysosomal drug sequestration
Doxorubicin has been shown to accumulate in cellular
lysosomes in a variety of cell types, including those of
myeloid lineage [33,34]. Based on the drug resistant and
myeloid-like character of the CSF-1Rhigh cells, we
Mono 
























Figure 4 Canine hemangiosarcoma cells express ABCB1 and
ABCG2. (A) Cell surface expression of the ABC transporters by COSB
and (B) DD-1 cells was assessed using flow cytometry. Positive
staining is indicated by the solid black lines, and the isotype controls
are represented as shaded regions. MFI =mean fluorescence intensity.
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and CSF-1Rhigh cells from the COSB cell line. Cells were
incubated with doxorubicin for 1 hour followed by wash-
ing and further incubation for 24 hours in drug-free
medium. The relative levels of doxorubicin remaining in
both subpopulations were analyzed by flow cytometry to
detect doxorubicin fluorescence. The levels of doxorubicin
were significantly higher in the CSF-1Rhigh cells than inthe CSF-1Rlow cells at t = 0 (p = 0.005) and t = 24 hours
(p = 0.03) (Figure 6).
Based on these data, we surmised that the CSF-1Rhigh
cells might have a higher lysosomal capacity for drug se-
questration than their CSF-1Rlow counterparts. To test
this, we labeled the CSF-1Rhigh cells in the COSB and
AS5 cell lines with the same antibody used for the cell
enrichment process. This was followed by incubation
with increasing concentrations of LysoTracker DeepRed
in order to compare the relative lysosomal sequestration
capacity between the cell subpopulations. Both the CSF-
1Rlow and the CSF-1Rhigh cell populations showed an
increase in relative fluorescence as the LysoTracker con-
centration was increased; however, the relative Lyso-
Tracker fluorescence in the CSF-1Rhigh cells ranged
from approximately 1.5- to 2.5-fold higher between all
concentrations tested (Figure 7A and B and Additional
file 1: Table S3). Our data also indicate that the CSF-
1Rhigh cell population is more heterogeneous than the
CSF-1Rlow population. This is evident in the COSB CSF-
1Rhigh cell population (Figure 7A) where a bimodal dis-
tribution becomes pronounced as the concentration of
LysoTracker is increased; however a small “high” popu-
lation also is evident in the CSF-1Rlow cells. For the AS5
cell line, the histograms were broader for the CSF-1Rhigh
populations compared to those from the CSF-1Rlow pop-
ulations, potentially indicating a wider distribution of
lysosomal capacity and heterogeneity.
Our results show that cells with high CSF-1R expres-
sion enriched from hemangiosarcoma and angiosarcoma
cell lines are more drug resistant than cells with low ex-
pression of the receptor. The data suggest that this re-
sistance may be achieved, in part, through increased
ABC transporter expression and/or drug sequestration
within cellular lysosomes. Our results also suggest the
idea that the CSF-1Rhigh cells have a greater lysosomal
capacity, and further isolation via cell sorting and
characterization these cells might be achieved using dual
staining of CSF-1Rhigh in combination with LysoTracker
analysis.
CSF-1Rhigh cells show exclusive expression of CD133
Finally, we sought to determine if CSF-1R was co-
expressed with the stem and progenitor cell markers
CD34, CD117, and CD133, since these markers have
been associated with tumor initiating cells and as well as
drug resistance [35,36]. A bimodal expression pattern
for CD34 was noted in all of the canine hemangiosar-
coma cell populations (Figure 8A and B). In particular,
CSF-1Rhigh cells had a higher percentage of CD34bright
cells than cells from the unenriched monolayers and
CSF-1Rlow subsets. Expression of CD117 was variable in
the CSF-1Rlow populations from COSB and DD-1, but
higher expression was noted in the CSF-1Rhigh populations.

























   Monolayer             CSF-1Rlow             CSF-1Rhigh 
DR=94.1% DR=92.4% DR=98.8% 
SP=3.6% SP=0.8% SP=4.7% 
DR=97.5% DR=96.6% DR=99.5% 
SP=0.5% SP=0.7% SP<0.1% 
DR=94.8% DR=94.4% DR=96.1% 





Figure 5 (See legend on next page.)
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Figure 5 Dye exclusion identifies side populations in unenriched monolayers, CSF-1Rlow, and CSF-1Rhigh populations. A. DyeCycle Violet
efflux was measured in monolayer, CSF-1Rlow, and CSF-1Rhigh cells to identify side population (SP) and dye retaining (DR) cells by COSB and
(B) DD-1 cells. Verapamil was used to inhibit dye efflux. Propidium iodide was added immediately before analysis of all samples in order to
exclude dead cells from analysis.
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in the DD-1 cell line, indicating heterogeneity within the
CSF-1Rhigh cell population. Interestingly, CD133 expres-
sion was restricted to the CSF-1Rhigh cell population in
both canine cell lines, indicating the CD133 expression also
may be used to distinguish drug resistant cells. In contrast,
expression of CD133 was not observed in the AS5 angio-
sarcoma cell line (Additional file 2: Figure S3). However,
CD34 and CD117 were expressed in all of the cell popula-
tions although higher expression was observed in the
monolayer and CSF-1Rlow cell populations.
Discussion
Human angiosarcoma and canine hemangiosarcoma are
aggressive vascular tumors where there are currently no
effective treatments [2,3,37]. Angiogenesis and inflam-
mation are key features of hemangiosarcoma [7,8], and
progenitor cell populations expressing markers of both
endothelial and myeloid progenitors support this prem-
ise [8]. Because these cells may participate in both the
angiogenic and inflammatory responses, a better under-
standing of the cell biology would provide insight into
new therapeutic opportunities. Here, we show that cell
populations enriched for the myeloid marker, CSF-1R,
are highly drug resistant in hemangiosarcoma and angio-
sarcoma, and this resistance may be mediated through




























Figure 6 CSF-1Rhigh cells show increased retention of
doxorubicin. COSB cells were incubated with 1 μM doxorubicin
and the levels of doxorubicin and CSF-1R expression were measured
by flow cytometry immediately after incubation (t = 0) and 24 hours
later (t = 24). The levels of doxorubicin were significantly higher in
the CSF-1Rhigh cells than in the CSF-1Rlow cells at t = 0 (p = 0.005)
and t = 24 hours (p = 0.03).Lysosomes have been shown to be involved in the se-
questration of amine-containing drugs such as doxo-
rubicin [38,39]. The sequestration of drugs away from
cellular target sites into cytoplasmic organelles prevents
the drugs from reaching their targets of interest, lead-
ing to ineffective drug therapy. In support of this mech-
anism, our results suggest that a small population of
cells identified by CSF-1R expression is more resistant
due to doxorubicin sequestration into what are likely
cellular lysosomes. While further studies are needed,
the more myeloid-like character of the CSF-1Rhigh cells
may play a role. Prior studies using human myeloid
leukemia cell lines demonstrated that the more drug re-
sistant variants of the lines showed increased drug se-
questration within lysosomes [33,34]. As a consequence
of the increased lysosomal drug trapping, nuclear accu-
mulation of the drug was decreased leading to lower
cytotoxicity [34].
More recently, Sukhai et al. showed that lysosomes
isolated from primary human acute myeloid leukemia
(AML) cells, CD34+ AML progenitor cells, as well as hu-
man and mouse AML cell lines contained larger lyso-
somes when compared to lysosomes found in normal
human CD34+ hematopoietic cells [40]. Although larger
in size, the number of lysosomes per cell did not differ
significantly between AML cells and normal cells. Alter-
ations in lysosomal size may be indicative of altered
metabolic processes, specifically alterations in fatty acid
metabolism [41], which may be important for altered en-
ergy needs of cancer cells. Furthermore, primary human
AML and AML progenitor cells were more sensitive to
the antimalarial agent mefloquine, a quinoline approved
for the treatment of malaria and known to accumulate
in the lysosomes of the malarial parasite [42]. These ob-
servations provide the rationale for therapeutically tar-
geting the lysosomal compartment in AML, and they
also support the investigation of the effects of lysosomal
disruption on hemangiosarcomas and angiosarcomas
since this approach may target the more drug resistant
CSF-1Rhigh cells.
While it is likely that doxorubicin is sequestered in
cellular lysosomes largely due to its lysosomotropic
properties [34], drug sequestration within lysosomes also
may be due to ABC transporter activity. Chapuy et al.
determined that the ABCA3 transporter expression was
localized to lysosome and multivesicular body mem-
branes in AML, and that ABCA3 expression was associ-
ated with unfavorable treatment outcomes for AML
A 









= 0 nM = 5 nM = 25 nM = 50 nM [LysoTracker] 



















































Figure 7 CSF-1Rhigh cells preferentially accumulate higher levels of LysoTracker. (A) COSB and AS5 were stained for cell surface CSF-1R
expression using an RPE-labeled CSF-1R antibody followed by incubation with increasing concentrations of LysoTracker DeepRed. LysoTracker
fluorescence was assessed in the CSF-1Rhigh cell population (approximately 1-2% of all cells), and this fluorescence was compared to the CSF-1Rlow cell
population (dimmest 3-5% of all cells) in each cell line. The fluorescence intensity of cells without LysoTracker or with increasing concentrations of
LysoTracker added to the CSF-1Rlow and CSF-1Rhigh cell populations is shown. For the AS5 studies, the coefficient of variation (CV) values are provided
as [LysoTracker concentration (CSF-1Rlow, CSF-1Rhigh)] for comparison of the histograms: [0 nm (39.4, 88.9); 5 nm (61.2, 109); 25 nM (78.3, 97.6); 50 nM
(65.2, 86.3] (B) The relative fluorescence levels for each population compared to the untreated controls were plotted against the increasing LysoTracker
concentrations. The graphs represent the data presented from each cell line in panel A.
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(CML) showed that lysosomal storage capacity was in-
creased with increases in ABCA3 expression, indicating
that ABCA3 may contribute to drug resistance by facilitat-
ing lysosomal drug sequestration [44]. ABCA3 expression
appeared to be low across a population of cells with high
CSF-1R expression enriched from hemangiosarcoma
cell lines when expression was examined usingmicroarray anlaysis (J-H. Kim, unpublished observation).
Thus ABCA3 may not contribute to lysosomal sequestra-
tion in hemangiosarcomas. In contrast, ABCB1 expression
on lysosomes has been identified and may contribute to
doxorubicin sequestration since doxorubicin accumula-
tion was inhibited in the presence of the ABCB1 inhibitor
valspodar [45]. Thus, further studies examining ABCB1
















































Figure 8 Canine hemangiosarcoma cells express CD34, CD117, and CD133. (A) Cell surface expression of CD34, CD117, and CD133 by COSB
and (B) DD-1 cells was assessed using flow cytometry. Positive staining is indicated by the solid black lines, and the isotype controls are represented
as shaded regions. MFI =mean fluorescence intensity.
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be identified through microarray analysis.
Although the hemangiosarcoma and angiosarcoma cell
lines showed similar drug resistance mechanisms and
these populations could be enriched by targeting CSF-
1R expression, the cell surface marker expression pro-
files differed between species. Previous studies using
hemangiosarcoma cell lines demonstrated expression of
early hematopoietic (CD34, CD117, and CD113) and
endothelial progenitor (CD34 and CD133) markers [6].
While expression of CD34 and CD117 by both the CSF-
1Rlow and CSF-1Rhigh cells was observed in the heman-
giosarcoma cell lines, expression of CD133 was exclusive
to the CSF-1Rhigh cell subpopulation. The retention of
CD133 expression by the CSF-1Rhigh cell population
brings up the intriguing possibility in hemangiosarcomas
that the CSF-1Rhigh cell population possesses the poten-
tial for differentiation into CSF-1Rlow cells and may be
responsible for maintaining tumor growth autocrine or
paracrine loops since we previously determined that the
ligands for CSF-1R, CSF-1 and IL-34, are expressed by
these and other canine hemangiosarcoma cell lines (B. H.
Gorden, unpublished data). Studies using cell sorting of
lineage markers or single cell isolation followed by clonal
expansion would address both hypotheses, but our group
has not yet undertaken these approaches.
In contrast, expression of CD34 and CD117 were ob-
served mainly in the monolayer and the CSF-1Rlow cell
population from the AS5 cell line, although some ex-
pression was observed in the CSF-1Rhigh cells. We did
not detect expression of CD133. Our results are similar
to those reported by Lui et al. where the expression of
both CD34 and CD117 was detected in angiosarcomas
by immunohistochemistry. In keeping with our observa-
tions for CD133, detection of CD133 expression by im-
munohistochemistry was negative overall [9]. In both
cases, the expression levels of CD133 may have been
below the detection limit by immunohistochemistry due
to cellular differentiation or tumor heterogeneity and
this may also be the case for flow cytometry [9]. Regard-
less, the overall expression of these markers in the AS5
cell line reflects previous findings, and they also high-
light that differences do exist between human angiosar-
comas and canine hemangiosarcomas at the cellular and
molecular level even though their overall pathologies ap-
pear to be virtually indistinct. Further studies are needed
to characterize the potential differences as well as the
noted similarities between these tumors.
Conclusions
We present the finding that cells with high CSF-1R ex-
pression are more drug resistant than cells with low
levels of CSF-1R expression in hemangiosarcoma and
angiosarcoma cell lines. Investigation of the mechanisticbasis of the selective resistance revealed increased lyso-
somal capacity in CSF-1Rhigh cells enriched from canine
hemangiosarcoma and human angiosarcoma cell lines as
a potential mechanism. Our results highlight drug resist-
ance as a common feature in representative cell lines
from both sarcomas, further justifying how studies in
dogs may be especially relevant to understanding drug
resistance mechanisms of the human disease. The identi-
fication of these populations also offers a unique model to
study the development and progression of vascular sarco-
mas in addition to providing a way to predict responses to
therapy and identify new treatment approaches.
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